A retrospective cohort study assessing the persistence and adherence with oral trifluridine/tipiracil or regorafenib in patients with Colorectal cancer
Latest Information Update: 28 Feb 2022
At a glance
- Drugs Regorafenib (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
Most Recent Events
- 28 Feb 2022 New trial record
- 22 Jan 2022 Results presented at the 2022 Gastrointestinal Cancers Symposium